GoodRx Holdings, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx First Quarter 2022 Earnings Call. At this time, as a reminder, today's conference call is being recorded. I would now like to introduce your host for today's call, Whitney Notaro, Vice President of Investor Relations. Ms. Notaro, you may begin.

Thank you, Operator. Good afternoon, everyone. and welcome to GoodRx's earnings conference call for the first quarter of 2022. Joining me today are Doug Hirsch and Trevor Bedzek, our co-founders and co-chief executive officers, and Carsten Voormann, our chief financial officer. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, and the expected impact of COVID-19 on our business. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors. These factors may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Factors discussed in the risk factors section of our quarterly report on Form 10-Q for the quarter ended March 31, 2022, and our other filings with the Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change. In addition, we may also reference certain non-GAAP metrics which are reconciled to the nearest gap metric in the company's shareholder letter, which can be found on the overview page of our investor relations website at investors.goodrx.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well. With that, I'll turn it over to Doug.

Good afternoon, and thank you all for joining us today. When Trevor and I started GoodRx, our mission was clear. We knew we had to help Americans get the health care they need at a price they can afford. To build a strong and sustainable business from the ground up, we knew that both the product and the team would be key to our success. Fast forward to over a decade later, GoodRx has become a trusted brand that is loved by both consumers and healthcare professionals. GoodRx was also recently named to Time's list of the 100 most influential companies of 2022. This recognition is a testament to the amazing work and extraordinary impact of our team. It's exciting to think about how far we have come. GoodRx's unique, proprietary, and extensible platform has now saved consumers a cumulative $40 billion. Our curious, passionate, and highly motivated team is now, with the addition of VitaCare, almost 1,000 strong, and we have a highly profitable business growing 27% year over year. We believe the opportunity ahead is significant, and we're just getting started. That is why I am thrilled to announce that we're continuing to bolster our leadership team with a number of new hires we've made in the past few months, Raj Barry will be joining GoodRx as Chief Operating Officer later this month, and we've recently welcomed Mark Hull, our Chief Product Officer, Veena Lait, our Chief People Officer, and Scott Paul, our SVP of Healthcare and Consumer Innovation. These innovative, forward-thinking leaders believe in our vision and share our passion to improve the state of healthcare in America. We believe their respective expertise and exceptional experience will be invaluable as we continue to grow and scale our business. As Chief Operating Officer, Raj will lead continued growth and expansion at GoodRx while helping increase value across the prescriptions business. He brings more than 20 years of operational leadership experience at fast-paced, innovative companies, including Uber, where he most recently served as Vice President of Global Grocery and New Vertical. As Chief Product Officer, Mark leads product strategy and management at GoodRx and is focused on building industry-leading solutions for consumers, providers, and pharmacists. With over 25 years of experience in product management at companies including Meta and LinkedIn, he has built world-changing products that have had an incredible impact on billions of people. As Chief People Officer, Veena leads our HR strategy and operations. She is a transformational HR leader who brings her extensive experience at global, fast-growing technology companies, including the Trade Desk, and her passion for employee development and engagement to GoodRx. As SVP of Healthcare and Consumer Innovation, Scott works closely with senior leadership on all areas of healthcare innovation across the ecosystem of consumers, retailers, PBMs, providers, and drug manufacturers, leveraging his substantial healthcare experience and knowledge. Scott previously founded Apex Affinity, where he created and ran many of the large pharmacy discount programs in the market, and most recently served as EVP at MedImpact, where he focused primarily on consumer savings. We are very excited to be adding these exceptional leaders to the team, and look forward to accelerating GoodRx's accomplishments together. With that, I'll turn it over to Trevor to address key highlights from the quarter and trends in our business.